'Love at First Sight'
Infinity Licenses PI3K Program From Intellikine in $489M Deal
By Trista Morrison
Friday, July 9, 2010
Infinity Pharmaceuticals Inc. signed a $488.5 million global licensing deal for Intellikine Inc.'s preclinical phosphoinositide-3 kinase (PI3K) delta and gamma inhibitors, including lead compound INK1197, an oral small molecule slated to begin clinical trials for inflammatory diseases in 2011. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.